Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma
Allison E. Drew(Epizyme (United States)), Scott Ribich(Blueprint Medicines (United States))
Cited by 136
Related Papers
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
|The Lancet Oncology|2018|614
Membrane Association and Protein Conformation of α-Synuclein in Intact Neurons
|Journal of Biological Chemistry|2000|239